Delay Antiretroviral Therapy in HIV Patients With Cryptococcal Meningitis, Researchers Recommend
November 5, 2012
Dr. David Boulware, professor of infectious diseases and international medicine at the University of Minnesota in Minneapolis, advised that in treatment-naive HIV patients with cryptococcal meningitis, the meningitis should be treated until the patients' cerebrospinal fluid (CSF) is cleared of the infection before antiretroviral therapy (ART) is administered. Boulware was speaking at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. He made these recommendations based on a study that examined ART and delayed ART in ART-naive HIV patients with cryptococcal meningitis in Uganda and South Africa.
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.